| Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy (NCT06693037) | Shu Wang | 2019-01-01 |
| A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (NCT03811418) | iOMEDICO AG | 2019-01-01 |
| Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer (NCT06693024) | Shu Wang | 2019-01-01 |
| Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy (NCT06711068) | Shu Wang | 2019-01-01 |
| Tw HER2 Positive Breast Cancer Productivity & Utility Study (NCT04011085) | Taiwan Epidemiology Association | 2018-12-24 |
| Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer (NCT03755141) | National Cancer Center, Korea | 2018-12-15 |
| T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (NCT03530696) | University of Arizona | 2018-12-06 |
| HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases (NCT03696030) | City of Hope Medical Center | 2018-11-27 |
| Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients. (NCT03735966) | Henan Cancer Hospital | 2018-11-20 |
| MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC (NCT03881605) | Sunnybrook Health Sciences Centre | 2018-11-08 |
| Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer (NCT03709082) | University of Kansas Medical Center | 2018-10-15 |
| Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib (NCT03094052) | University of California, San Francisco | 2018-10-09 |
| Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy (NCT03684863) | Shandong Cancer Hospital and Institute | 2018-10-01 |
| 18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response (NCT04756921) | Biyun Wang, MD | 2018-09-01 |
| A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer (NCT03655353) | Henrik Lindman | 2018-08-22 |
| Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer (NCT04957212) | Cinnagen | 2018-08-11 |
| Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (NCT03571633) | Centre Leon Berard | 2018-08-06 |
| Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer (NCT03588091) | Jiangsu HengRui Medicine Co., Ltd. | 2018-07-24 |
| Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer (NCT03556358) | Tanvex BioPharma USA, Inc. | 2018-06-28 |
| HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (NCT03387553) | H. Lee Moffitt Cancer Center and Research Institute | 2018-06-06 |
| Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer (NCT06107790) | Zhejiang Hisun Pharmaceutical Co. Ltd. | 2018-05-16 |
| Adapted Physical Activity for Breast Cancer HER2 Positive Patient (NCT02963363) | Centre Jean Perrin | 2018-04-27 |
| A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases (NCT03500380) | RemeGen Co., Ltd. | 2018-04-24 |
| Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy (NCT04276337) | Samsung Medical Center | 2018-03-01 |
| Omission of Radiation in Patients With Her-2 Positive Breast Cancer (NCT03460067) | University of Kansas Medical Center | 2018-02-23 |
| Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer (NCT03384914) | H. Lee Moffitt Cancer Center and Research Institute | 2018-02-19 |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients (NCT03013504) | Prestige Biopharma Limited | 2018-02-19 |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (NCT03319459) | Fate Therapeutics | 2018-01-18 |
| Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients (NCT03281824) | Alteogen, Inc. | 2018-01-11 |
| Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer (NCT03521245) | OmicsWay Corp. | 2017-10-01 |
| PRS-343 in HER2-Positive Solid Tumors (NCT03330561) | Pieris Pharmaceuticals, Inc. | 2017-09-13 |
| Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer (NCT03238495) | Qamar Khan | 2017-08-15 |
| TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (NCT03179904) | Mayo Clinic | 2017-08-03 |
| Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer (NCT03112590) | H. Lee Moffitt Cancer Center and Research Institute | 2017-06-23 |
| Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer (NCT03125928) | Fox Chase Cancer Center | 2017-06-13 |
| A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin (NCT03085368) | Peking Union Medical College Hospital | 2017-03-01 |
| Denosumab as an add-on Neoadjuvant Treatment (GeparX) (NCT02682693) | GBG Forschungs GmbH | 2017-02-13 |
| TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer (NCT03140553) | Guangdong Provincial People's Hospital | 2016-09-01 |
| Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer (NCT07166367) | National Cancer Centre, Singapore | 2016-08-11 |
| Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) (NCT02705859) | Cancer Trials Ireland | 2016-04-01 |
| Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer (NCT02476539) | Tianjin Hemay Pharmaceutical Co., Ltd | 2015-10-14 |
| A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging (NCT02993198) | Northwestern University | 2015-04-01 |
| Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer (NCT02226276) | City of Hope Medical Center | 2015-01-07 |
| De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients (NCT06700369) | Shu Wang | 2015-01-01 |
| Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer (NCT06711055) | Shu Wang | 2015-01-01 |
| A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) (NCT02125344) | GBG Forschungs GmbH | 2014-12-01 |
| MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients (NCT02213744) | Merrimack Pharmaceuticals | 2014-07-01 |
| Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (NCT02345772) | Western Regional Medical Center | 2014-07-01 |
| BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx (NCT02038010) | Northwestern University | 2014-05-21 |
| Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection (NCT04170595) | Genor Biopharma Co., Ltd. | 2014-03-28 |
| Patients With Brain Metastases From HER2-positive Breast Cancer (NCT02135159) | Institut du Cancer de Montpellier - Val d'Aurelle | 2014-02-01 |
| PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer (NCT01712815) | University of Southern California | 2013-11-22 |
| Cardiac Safety Study in Patients With HER2 + Breast Cancer (NCT01904903) | Medstar Health Research Institute | 2013-10-01 |
| Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer (NCT01855828) | Yale University | 2013-09-01 |
| Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (NCT01912963) | Dana-Farber Cancer Institute | 2013-09-01 |
| Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy (NCT03738553) | University of Washington | 2013-08-01 |
| Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer (NCT01873833) | University of Southern California | 2013-07-29 |
| Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (NCT01730833) | City of Hope Medical Center | 2013-07-17 |
| Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis (NCT01783756) | Jonsson Comprehensive Cancer Center | 2013-06-26 |
| Pre Operative Trastuzumab in Operable Breast Cancer (NCT01785420) | Dr Rajendra A. Badwe | 2013-05-01 |
| Fasting on Newly Diagnosed Breast Cancer (NCT02379585) | Western Regional Medical Center | 2013-01-01 |
| Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer (NCT01729884) | University of Washington | 2012-12-01 |
| Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer (NCT01840306) | Cancer Trials Ireland | 2012-10-12 |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery (NCT01705340) | National Cancer Institute (NCI) | 2012-09-01 |
| Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer (NCT01632332) | Mayo Clinic | 2012-07-09 |
| Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer (NCT01688609) | National Cancer Institute (NCI) | 2012-07-01 |
| CharactHer. ICORG 12-09, V3 (NCT01722890) | Cancer Trials Ireland | 2012-07-01 |
| Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer (NCT01219907) | University of Washington | 2012-06-01 |
| HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025 (NCT02095210) | Dorte Nielsen | 2011-08-01 |
| Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer (NCT01355393) | University of Washington | 2011-07-01 |
| Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer (NCT01245205) | National Cancer Institute (NCI) | 2010-11-01 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (NCT01042379) | QuantumLeap Healthcare Collaborative | 2010-03-01 |
| Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer (NCT01100489) | Case Comprehensive Cancer Center | 2010-02-01 |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer (NCT01037790) | Abramson Cancer Center at Penn Medicine | 2009-10-01 |
| Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer (NCT00817362) | Infinity Pharmaceuticals, Inc. | 2009-03-01 |
| Vaccine Therapy in Treating Patients With Stage IV Breast Cancer (NCT00791037) | University of Washington | 2008-10-01 |
| Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (NCT00618657) | University of California, Irvine | 2008-02-01 |
| Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer (NCT00331552) | University of Washington | 2006-02-01 |
| Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer (NCT00077376) | National Cancer Institute (NCI) | 2005-03-01 |
| Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases (NCT00098605) | National Cancer Institute (NCI) | 2004-10-01 |
| Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer (NCT00343109) | University of Washington | 2004-03-01 |
| Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer (NCT00079326) | National Cancer Institute (NCI) | 2004-01-01 |
| Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery (NCT00194779) | University of Washington | 2003-10-01 |
| Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine (NCT00228358) | University of Washington | 2003-06-01 |
| Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer (NCT00039455) | National Cancer Institute (NCI) | 2002-04-01 |
| Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer (NCT00436254) | University of Washington | 2001-10-01 |
| Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer (NCT00006228) | National Cancer Institute (NCI) | 2000-07-01 |
| Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic (NCT00003440) | National Cancer Institute (NCI) | 1998-07-01 |
| An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic (NCT04395508) | Genentech, Inc. | |
| Margetuximab Expanded Access Program (NCT03133988) | TerSera Therapeutics LLC | |
| Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer (NCT04220203) | Seagen, a wholly owned subsidiary of Pfizer | |